RC
NERV icon

Rangeley Capital’s Minerva Neurosciences NERV Stock Holding History

Rangeley Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$21.1K – 149
2025
Q3 		$21.1K Buy
+10,000
New +$20.4K 0.02% 126

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rangeley Capital's NERV Position: Q4 2025 in Review

Rangeley Capital sold out of Minerva Neurosciences (NERV) in Q4 2025, closing a stake of 10,000 shares — an estimated $21.1K sold.

Rangeley Capital first reported a position in NERV in Q3 2025 and held it in 1 quarter. The position peaked at $21.1K in Q3 2025. 33 funds tracked by Wall St. Rank hold NERV as of Q4 2025.

  • Rangeley Capital reported no remaining Minerva Neurosciences position as of Q4 2025 after selling out during the quarter.
  • Rangeley Capital sold 10,000 Minerva Neurosciences shares in Q4 2025, an estimated $21.1K.
  • Rangeley Capital first reported a position in Minerva Neurosciences in Q3 2025 and held it in 1 quarter.
  • Rangeley Capital's Minerva Neurosciences position peaked at $21.1K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.